From the Journals

Empagliflozin Tested in Real-World Data

Investigators assess whether EMPA-REG findings extend to broader patients with type 2 diabetes.

Share

Empagliflozin, a sodium–glucose cotransporter 2 inhibitor, has been linked to reduced all-cause mortality in type 2 diabetes patients compared to dipeptidyl peptidase-4 inhibitors, according to a study that emulates randomized clinical trials. Analyzing electronic health records of 62,503 adults from 2014 to 2022, researchers showed that 83% of empagliflozin users wouldn't have qualified for the EMPA-REG trial. Over a follow-up period yielding 200,646 person-years, the adjusted hazard ratio for reduced mortality was 0.76, indicating a significant benefit in real-world settings, as confirmed by lead author David K. Ryan.

Original Source(s)

Empagliflozin Tested in Real-World Data

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Sleep Duration Signals Metabolic Change

Weekend sleep recovery shows mixed metabolic associations depending on weekday sleep duration.

The Oral GLP‑1 Era Has Arrived 

And chromatographers are about to be very busy…

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation